Substantial Susceptibility of Chronic Lymphocytic Leukemia to BCL2 Inhibition: Results of a Phase I Study of Navitoclax in Patients With Relapsed or Refractory DiseaseROBERTS, Andrew W; SEYMOUR, John F; YUE CUI et al.Journal of clinical oncology. 2012, Vol 30, Num 5, pp 488-496, issn 0732-183X, 9 p.Article

An open-label, phase 1 study evaluating safety, tolerability, and pharmacokinetics of linifanib (ABT-869) in Japanese patients with solid tumorsASAHINA, Hajime; TAMURA, Yosuke; CHIU, Yi-Lin et al.Cancer chemotherapy and pharmacology. 2012, Vol 69, Num 6, pp 1477-1486, issn 0344-5704, 10 p.Article

Phase II Study of Single-Agent Navitoclax (ABT-263) and Biomarker Correlates in Patients with Relapsed Small Cell Lung CancerRUDIN, Charles M; HANN, Christine L; RANSON, Malcolm R et al.Clinical cancer research (Print). 2012, Vol 18, Num 11, pp 3163-3169, issn 1078-0432, 7 p.Article

A novel multi-targeted tyrosine kinase inhibitor, linifanib (ABT-869), produces functional and structural changes in tumor vasculature in an orthotopic rat glioma modelYANPING LUO; FANG JIANG; FOX, Gerard B et al.Cancer chemotherapy and pharmacology. 2012, Vol 69, Num 4, pp 911-921, issn 0344-5704, 11 p.Article

Phase I Study of Navitoclax (ABT-263), a Novel Bcl-2 Family Inhibitor, in Patients With Small-Cell Lung Cancer and Other Solid TumorsGANDHI, Leena; CAMIDGE, D. Ross; DIVE, Caroline et al.Journal of clinical oncology. 2011, Vol 29, Num 7, pp 909-916, issn 0732-183X, 8 p.Article

Targeting DNA repair with combination veliparib (ABT-888) and temozolomide in patients with metastatic castration-resistant prostate cancerHUSSAIN, Maha; CARDUCCI, Michael A; ALUMKAL, Joshi J et al.Investigational new drugs. 2014, Vol 32, Num 5, pp 904-912, issn 0167-6997, 9 p.Article

Phase 2 Trial of Linifanib (ABT-869) in Patients With Unresectable or Metastatic Hepatocellular CarcinomaHANCHONGTOH; CHEN, Pei-Jer; JIANG QIAN et al.Cancer. 2013, Vol 119, Num 2, pp 380-387, issn 0008-543X, 8 p.Article